Skip to content

Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens

Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02480933
Acronym
SISYPHUS
Enrollment
768
Registered
2015-06-25
Start date
2016-09-30
Completion date
2020-09-30
Last updated
2017-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Breast Cancer, Male Breast Cancer

Brief summary

The aim of this study is to define silent breast cancer prevalence in both sexes and will be held by biopsies performed in imaging suspicious areas of the breast (ecography and mammography) in cadavers without known breast cancer.

Detailed description

Cadavers of both sexes are going to be submitted to bilateral mastectomy. The specimens are going to be examined by palpation, ecography and mammography and all areas with (Breast Imaging Reporting and Data System) BI-RADS classification \>= 3 are going to be biopsied. Biopsy specimens are going to be processed by the pathology department and cancers are going to be identified and classified by their molecular type. The investigators intend to know which is the disease reservoir in various ages.

Interventions

OTHERBiopsy

Biopsy of BI-RADS 3 and superior lesions

PROCEDUREBilateral mastectomy

Bilateral mastectomy and imaging study of cadaveric breasts

Sponsors

Instituto Nacional de Medicina Legal e Ciências Forenses, Delegação do Sul
CollaboratorUNKNOWN
Centro Hospitalar Lisboa Ocidental
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female and male cadavers above 40 years

Exclusion criteria

* Known breast cancer * Breast tissue accidental damage

Design outcomes

Primary

MeasureTime frameDescription
Silent breast cancer prevalence2 yearsTo define the existing disease that did not caused death in both sexes

Secondary

MeasureTime frameDescription
Silent breast cancer prevalent molecular profile2 yearsTo identify those molecular subgroups of the disease that remain silent

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026